디지털 치료제 시장 예측(-2032년) : 치료 유형별, 전개 형태별, 기술별, 용도별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Digital Therapeutics Market is accounted for $6.6 billion in 2025 and is expected to reach $29.5 billion by 2032 growing at a CAGR of 23.8% during the forecast period. Digital Therapeutics are evidence-based software applications designed to prevent, manage, or treat medical conditions through clinically validated digital interventions. Using behavioral science, cognitive therapies, real-time monitoring, and personalized treatment pathways, these platforms deliver measurable improvements in patient outcomes. They complement or substitute traditional therapies, especially in chronic disease management, mental health, metabolic disorders, and neurological conditions. Digital therapeutics operate under regulatory oversight and integrate with healthcare systems, ensuring data-driven care continuity and remote clinical support.

According to IQVIA's Digital Health Trends update, over 370 million unique patients now use prescription-grade digital therapeutics monthly, up from 110 million in 2020, signaling widespread clinical adoption for chronic disease management.

Market Dynamics:

Driver:

Growing adoption of remote patient management

Growing adoption of remote patient management is accelerating demand for digital therapeutics as healthcare ecosystems shift toward virtual care delivery. Rising prevalence of chronic conditions and increased comfort with telehealth platforms strengthen momentum. Digital tools enabling real-time monitoring, medication adherence tracking, and behavioral-health interventions offer measurable clinical benefits. As providers seek scalable, cost-efficient ways to manage large patient populations, digital therapeutics become essential in supporting continuous engagement, improving treatment adherence, and enhancing long-term health outcomes.

Restraint:

Limited reimbursement in many regions

Limited reimbursement in many regions continues to constrain large-scale adoption, particularly where regulatory pathways for software-based therapies remain underdeveloped. Payers often hesitate to classify digital therapeutics as reimbursable medical interventions, slowing integration into mainstream care. Fragmented evaluation standards and insufficient clinical-economic evidence further challenge funding decisions. As a result, providers and patients frequently bear out-of-pocket costs, impeding uptake. Until reimbursement frameworks mature globally, market penetration will remain uneven across different healthcare systems.

Opportunity:

Integration with personalized treatment pathways

Integration with personalized treatment pathways presents significant expansion potential as digital therapeutics increasingly leverage AI-driven insights, behavioral analytics, and patient-specific biomarkers. Tailored treatment programs improve efficacy, enhance engagement, and reduce relapse rates across chronic, metabolic, and mental-health disorders. Growing availability of real-world evidence strengthens clinical validation, encouraging adoption within evidence-based care models. As healthcare shifts toward precision medicine, digital platforms offering individualized therapy optimization gain prominence as key enablers of patient-centric interventions.

Threat:

Data-security breaches impacting patient trust

Data-security breaches impacting patient trust remain a critical threat as digital therapeutics rely heavily on sensitive behavioral, clinical, and biometric data. Cyber vulnerabilities in cloud infrastructure, mobile applications, and API integrations can lead to exposure of personal health information, eroding user confidence. Regulatory non-compliance may result in penalties and disrupt device approvals. Heightened public scrutiny around digital privacy could slow adoption unless platforms demonstrate robust cybersecurity frameworks and transparent data-handling practices.

Covid-19 Impact:

COVID-19 significantly accelerated digital therapeutics adoption as health systems prioritized remote care models during lockdowns. Patients increasingly adopted app-based interventions, digital cognitive-behavioral tools, and chronic-disease tracking platforms to avoid in-person visits. Clinical trials shifted to virtual formats, generating greater acceptance among regulators and providers. The pandemic heightened awareness of scalable digital care pathways, and post-pandemic demand remains strong as hybrid healthcare models persist, cementing digital therapeutics' long-term role in treatment delivery.

The chronic disease management systems segment is expected to be the largest during the forecast period

The chronic disease management systems segment is expected to account for the largest market share during the forecast period, resulting from rising prevalence of diabetes, cardiovascular disorders, respiratory diseases, and lifestyle-driven conditions. These platforms deliver structured monitoring, behavioral coaching, and therapy reinforcement, improving patient self-management. Providers increasingly rely on such systems to reduce hospitalizations, optimize care coordination, and enhance treatment adherence. Their proven clinical impact and broad applicability ensure sustained dominance in the digital therapeutics landscape.

The cloud-based platforms segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cloud-based platforms segment is predicted to witness the highest growth rate, propelled by their scalability, interoperability, and seamless data integration across healthcare systems. Cloud architectures enable real-time analytics, remote access, and continuous patient engagement at lower operational costs. They support multi-device synchronization, facilitating long-term monitoring and automated therapy adjustments. As demand rises for flexible, secure, and easily deployable digital-health solutions, cloud-based platforms rapidly emerge as the fastest-expanding segment.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, attributed to expanding digital-health initiatives, rapid smartphone penetration, and increasing burden of chronic diseases. Governments across China, India, Japan, and South Korea are accelerating adoption of remote-care programs and app-based therapeutic tools. Rising healthcare digitalization, favorable telemedicine regulations, and large patient populations further drive uptake. These conditions firmly position Asia Pacific as the leading market for digital therapeutics deployment.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR associated with strong reimbursement progress, rapid integration of digital therapeutics into clinical workflows, and robust venture-capital funding. The presence of leading digital-health innovators, supportive regulatory frameworks, and expanding partnerships between providers and technology firms accelerates adoption. Growing emphasis on outcome-based care and widespread acceptance of remote therapeutic interventions reinforce North America's status as the fastest-growing regional market.

Key players in the market

Some of the key players in Digital Therapeutics Market include Pear Therapeutics, Teladoc Health, Propeller Health, Omada Health, Welldoc, Noom, Akili Interactive, Click Therapeutics, Biofourmis, Kaia Health, Livongo (Teladoc), Mahana Therapeutics, Voluntis, Happify Health, Better Therapeutics, Big Health and BehaVR.

Key Developments:

In November 2025, Noom introduced Noom Med, combining digital therapeutics with telehealth prescribing for obesity and metabolic disorders, integrating behavioral science with AI-driven personalized coaching for sustainable health outcomes.

In October 2025, Noom introduced Noom Med, combining digital therapeutics with telehealth prescribing for obesity and metabolic disorders, integrating behavioral science with AI-driven personalized coaching for sustainable health outcomes.

In September 2025, Akili Interactive expanded its FDA-cleared digital therapeutic EndeavorRx, adding gamified modules for ADHD and cognitive disorders, while advancing clinical trials for broader neurological applications.

Treatment Types Covered:

• Behavioral Health Programs
• Chronic Disease Management Systems
• Physical Rehabilitation Platforms
• Lifestyle & Nutrition Interventions
• Neurological Therapy Programs
• Substance Use & Addiction Therapy

Deployments Covered:

• Cloud-Based Platforms
• On-Premise Platforms
• Hybrid Digital Therapy Systems
• Subscription-Based Platforms
• Integrated Hospital Platforms

Technologies Covered:

• AI-Based Therapy Platforms
• Mobile & App-Based Solutions
• Wearable-Integrated Systems
• Remote Monitoring Technologies
• VR/AR Therapy Platforms
• Data Analytics & Cloud Systems

Applications Covered:

• Diabetes & Metabolic Disorders
• Mental Health Disorders
• Cardiovascular Diseases
• Respiratory Disorders
• Pain Management
• Obesity & Lifestyle Disorders

End Users Covered:

• Hospitals & Clinics
• Employers & Corporate Wellness
• Pharmaceutical Companies
• Research Organizations
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Technology Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Digital Therapeutics Market, By Treatment Type

• 5.1 Introduction
• 5.2 Behavioral Health Programs
• 5.3 Chronic Disease Management Systems
• 5.4 Physical Rehabilitation Platforms
• 5.5 Lifestyle & Nutrition Interventions
• 5.6 Neurological Therapy Programs
• 5.7 Substance Use & Addiction Therapy

6 Global Digital Therapeutics Market, By Deployment

• 6.1 Introduction
• 6.2 Cloud-Based Platforms
• 6.3 On-Premise Platforms
• 6.4 Hybrid Digital Therapy Systems
• 6.5 Subscription-Based Platforms
• 6.6 Integrated Hospital Platforms

7 Global Digital Therapeutics Market, By Technology

• 7.1 Introduction
• 7.2 AI-Based Therapy Platforms
• 7.3 Mobile & App-Based Solutions
• 7.4 Wearable-Integrated Systems
• 7.5 Remote Monitoring Technologies
• 7.6 VR/AR Therapy Platforms
• 7.7 Data Analytics & Cloud Systems

8 Global Digital Therapeutics Market, By Application

• 8.1 Introduction
• 8.2 Diabetes & Metabolic Disorders
• 8.3 Mental Health Disorders
• 8.4 Cardiovascular Diseases
• 8.5 Respiratory Disorders
• 8.6 Pain Management
• 8.7 Obesity & Lifestyle Disorders

9 Global Digital Therapeutics Market, By End User

• 9.1 Introduction
• 9.2 Hospitals & Clinics
• 9.3 Employers & Corporate Wellness
• 9.4 Pharmaceutical Companies
• 9.5 Research Organizations
• 9.6 Other End Users

10 Global Digital Therapeutics Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Pear Therapeutics
• 12.2 Teladoc Health
• 12.3 Propeller Health
• 12.4 Omada Health
• 12.5 Welldoc
• 12.6 Noom
• 12.7 Akili Interactive
• 12.8 Click Therapeutics
• 12.9 Biofourmis
• 12.10 Kaia Health
• 12.11 Livongo (Teladoc)
• 12.12 Mahana Therapeutics
• 12.13 Voluntis
• 12.14 Happify Health
• 12.15 Better Therapeutics
• 12.16 Big Health
• 12.17 BehaVR